KIMS Hospitals Q4 FY26 Revenue Surges 35% YoY to ₹1,084 Cr, PAT at ₹33 Cr
KIMS Hospitals reported Q4 FY26 consolidated revenue of ₹1,084 Cr (up 35.3% YoY) and EBITDA of ₹216 Cr (up 6.8% YoY). PAT was ₹33 Cr. For FY26, revenue was ₹3,931 Cr (up 28.2% YoY) with PAT at ₹242 Cr. ARPOB grew 13.7% and ARPP grew 14% in Q4 FY26.
The significant revenue growth is positive, but the decline in PAT and EBITDA margins could be a concern for investors. The operational growth and clinical successes provide a balanced outlook.
While revenue and EBITDA showed strong year-on-year growth, PAT and EBITDA margins declined, indicating a mixed financial performance. The clinical achievements are positive but do not outweigh the financial concerns.
Krishna Institute of Medical Sciences Limited (KIMS Hospitals) has announced its audited financial results for the quarter and financial year ended March 31, 2026. The company reported a consolidated revenue of ₹1,084 crore for Q4 FY26, marking a significant year-on-year growth of 35.3% and a quarter-on-quarter growth of 8.1%. The Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) stood at ₹216 crore, an increase of 6.8% year-on-year and 5.9% quarter-on-quarter. However, the EBITDA margin was reported at 19.9% for Q4 FY26, compared to 25.3% in Q4 FY25 and 20.4% in Q3 FY26. Profit After Tax (PAT) for the quarter was ₹33 crore, a decrease from ₹106 crore in Q4 FY25 and ₹52 crore in Q3 FY26.
For the full financial year 2026, total revenue reached ₹3,931 crore, a growth of 28.2% year-on-year. EBITDA for FY26 was ₹828 crore, a marginal increase of 1.6% year-on-year. The EBITDA margin for the full year was 21.1%, down from 26.6% in FY25. PAT for FY26 was ₹242 crore, a decline from ₹415 crore in FY25. Consolidated Earnings Per Share (EPS) for FY26 stood at ₹6.03, a decrease of 37.2% year-on-year.
Operationally, for Q4 FY26, Average Revenue Per Operating Bed (ARPOB) grew by 13.7% year-on-year and 1.7% quarter-on-quarter, while Average Realization Per Patient (ARPP) grew by 14% year-on-year and 3.5% quarter-on-quarter. For the full year FY26, ARPOB grew by 14% year-on-year and ARPP grew by 11.4% year-on-year. Inpatient (IP) and Outpatient (OP) volumes saw growth of 15.4% and 25.4% respectively year-on-year.
The company also highlighted several clinical achievements across its hospitals during Q4 FY26, including India's first smart Cochlear implant surgery, successful VV-ECMO support, complex surgeries for jaundice and pancreatic cancer, and advanced procedures for stroke risk and ovarian cancer.
Dr. B Bhaskara Rao, CMD, KIMS Hospitals, stated that FY26 has been a year of accomplishments, with new units showing progress and new doctor additions reinforcing the KIMS brand. He expressed optimism for FY27 to meet set targets.
What to do with a filing like this
Krishna Institute of Medical Sciences Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Krishna Institute of Medical Sciences Limited. Read the original for the full detail.